Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P57078

UPID:
RIPK4_HUMAN

ALTERNATIVE NAMES:
Ankyrin repeat domain-containing protein 3; PKC-delta-interacting protein kinase

ALTERNATIVE UPACC:
P57078; Q96KH0

BACKGROUND:
The protein Receptor-interacting serine/threonine-protein kinase 4, with alternative names Ankyrin repeat domain-containing protein 3 and PKC-delta-interacting protein kinase, is crucial for the development of stratified epithelial tissues. It acts as a direct target of TP63 and plays a role in activating NF-kappa-B, a key factor in immune response and cell survival.

THERAPEUTIC SIGNIFICANCE:
Its association with diseases such as Bartsocas-Papas syndrome and CHAND syndrome highlights the therapeutic potential of targeting Receptor-interacting serine/threonine-protein kinase 4. Exploring its functions and interactions could lead to novel treatments for these rare genetic conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.